Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2014; 20(20): 5987-5998
Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.5987
Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.5987
Value of radiofrequency ablation in the treatment of hepatocellular carcinoma
Kai Feng, Kuan-Sheng Ma, Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
Author contributions: Ma KS designed the study; Feng K wrote the article.
Supported by National Natural Science Foundation of China, No. 81272688; and Foundation of State Key Laboratory of Trauma, Burn and Combined Injury, No. SKLKF201209
Correspondence to: Kuan-Sheng Ma, Professor, Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, No. 30 Gaotanyanzheng Street, Shapingbei District, Chongqing 400038, China. makuansheng@vip.sina.com
Telephone: +86-23-687765813 Fax: +86-23-68765812
Received: September 12, 2013
Revised: February 21, 2014
Accepted: April 1, 2014
Published online: May 28, 2014
Processing time: 258 Days and 10.4 Hours
Revised: February 21, 2014
Accepted: April 1, 2014
Published online: May 28, 2014
Processing time: 258 Days and 10.4 Hours
Core Tip
Core tip: The pivotal role of radiofrequency ablation (RFA) has recently been established among the various treatment strategies for hepatocellular carcinoma (HCC), primarily due to its excellent local tumor control. RFA may be complementary to the other treatments with curative intent for HCC and its beneficial outcomes in patients have been demonstrated in several clinical studies.